ASO Author Reflections : Registry-Based Analysis of Radiation-Associated Angiosarcoma of the Breast Provides Unbiased Insights into this Disease by Salminen, Samuli H. & Blomqvist, Carl P.
ASO AUTHOR REFLECTIONS
ASO Author Reflections: Registry-Based Analysis of Radiation-
Associated Angiosarcoma of the Breast Provides Unbiased
Insights into this Disease
Samuli H. Salminen1,2 , and Carl P. Blomqvist1,2
1Comprehensive Cancer Center, Helsinki University Hospital (HUH), Helsinki, Finland; 2University of Helsinki, Helsinki,
Finland
PAST
Radiation-associated angiosarcoma of the breast
(RAASB) is increasingly diagnosed in breast cancer sur-
vivors.1 Previous research has highlighted the importance
of radical surgery in the management of this disease.2
Unfortunately, most published research was performed in
single centers, possibly hampering the interpretation of
results. A recent registry-based analysis from The Nether-
lands reported a 5-year overall survival rate of 40.5%.3
PRESENT
We performed a comprehensive analysis of RAASB
patients identified from the database of the Finnish Cancer
Registry over 25 years.4 Thus, our study provides a unique
perspective of RAASB treatment and prognosis in a
nationwide population with complete follow-up of all
patients. We discovered that most RAASB patients are
eligible for radical surgery, and therefore possibly curative
treatment, emphasizing the importance of awareness of this
disease in the rapidly growing population of breast cancer
survivors. Forty-five percent of patients later had a local
recurrence, and planned lateral surgical margin was asso-
ciated with improved survival, therefore underlining the
impact of radical surgery. Furthermore, locally recurring
disease has a tendency to progress into a metastatic disease,
further impairing prognosis.
FUTURE
The evidence from this and previous studies suggests
that the primary treatment of a localized RAASB is radical
surgery.2–4 However, our study did not bring further clarity
into what surgical margins are needed for local control, due
to the retrospective nature of this rare disease and the lack
of comprehensive information for all patients.
Regrettably, a number of RAASB patients later progress
into metastatic disease.4 Due to the rarity of RAASB, few
patients are included in prospective trials of medical
treatment. Future work could build on the growing
knowledge on the molecular biology basis of RAASB to
perform prospective studies in the metastatic setting.
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